Articles   |    
Prolonged Enoxaparin Therapy to Prevent Venous Thromboembolism After Primary Hip or Knee Replacement
Philip C. Comp, MD, PhD; Theodore E. Spiro, MD; Richard J. Friedman, MD; Thomas L. Whitsett, MD; Gerhard J. Johnson, MD; Geoffrey A. Gardiner, Jr, MD; Glenn C. Landon, MD; Maurice Jové, MD, Enoxaparin Clinical Trial Group
View Disclosures and Other Information
A commentary is available with the electronic versions of this article, on our web site (www.jbjs.org) and on our CD-ROM (call 781-449-9780, ext. 140, to order).
Philip C. Comp, MD, PhD Department of Medicine, The University Hospitals, 800 N.E. 13th Street, Room EB400, Oklahoma City, OK 73126. E-mail address: philip-comp@uokhsc.edu
Theodore E. Spiro, MD Cardiovascular Therapeutic Area, European Operations Site, E2/309, Aventis Pharma, 20 Avenue Raymond Aron, 92160 Antony, France. E-mail address: theodore.spiro@aventis.com. Please address correspondence and requests for reprints to T.E. Spiro.
Richard J. Friedman, MD Medical University of South Carolina, 171 Ashley Avenue, Charleston, SC 29425
Thomas L. Whitsett, MD Department of Medicine, University of Oklahoma Health Sciences Center, Room 3120, 920 Stanton L. Young Boulevard, Oklahoma City, OK 73104
Gerhard J. Johnson, MD Veterans Administration Medical Center, One Veterans Drive, Minneapolis, MN 55417. E-mail address: johns337@maroon.tc.umn.edu
Geoffrey A. Gardiner Jr., MD Department of Radiology, Thomas Jefferson University Hospital, Suite 4200, Gibbons Building, 111 South 11th Street, Philadelphia, PA 19107
Glenn C. Landon, MD Kelsey-Seybold Clinic, St. Luke’s Medical Tower, 6624 Fannin Street, Houston, TX 77030
Maurice Jové, MD Atlanta Knee and Sports Medicine, 2801 North Decatur Road, Suite 200, Decatur, GA 30033
One or more of the authors has received or will receive benefits for personal or professional use from a commercial party related directly or indirectly to the subject of this article. Funds were received in total or partial support of the research or clinical study presented in this article. The funding source was Aventis Pharmaceuticals, Incorporated, Bridgewater, New Jersey, and Aventis Pharma, S.A., Antony, France, formerly Rhône-Poulenc Rorer Pharma, S.A., Collegeville, Pennsylvania, and Antony, France.

J Bone Joint Surg Am, 2001 Mar 01;83(3):336-336
5 Recommendations (Recommend) | 3 Comments | Saved by 3 Users Save Case


Background: Patients undergoing hip or knee joint replacement are at risk for venous thromboembolic complications for up to twelve weeks postoperatively. We evaluated the efficacy and safety of a prolonged post-hospital regimen of enoxaparin, a low-molecular-weight heparin, in this patient population.

Methods: Following elective total hip or knee replacement, 968 patients received subcutaneous enoxaparin (30 mg twice daily) for seven to ten days, and 873 were then randomized to receive three weeks of double-blind outpatient treatment with either enoxaparin (40 mg once daily) or a placebo. The primary efficacy end point was the prevalence of objectively confirmed venous thromboembolism or symptomatic pulmonary embolism during the double-blind phase of treatment.

Results: Of the 873 randomized patients, 435 underwent elective total hip replacement and 438 underwent elective total knee replacement. Enoxaparin was superior to the placebo in reducing the prevalence of venous thromboembolism in patients treated with hip replacement: 8.0% (eighteen) of the 224 patients treated with enoxaparin had venous thromboembolism compared with 23.2% (forty-nine) of the 211 patients treated with the placebo (p < 0.001; odds ratio, 3.62; 95% confidence interval, 2.00 to 6.55; relative risk reduction, 65.5%). Enoxaparin had no significant benefit in the patients treated with knee replacement: thirty-eight (17.5%) of the 217 patients treated with enoxaparin had venous thromboembolism compared with forty-six (20.8%) of the 221 patients treated with the placebo (p = 0.380; odds ratio, 1.24; 95% confidence interval, 0.76 to 2.02; relative risk reduction, 15.9%). Symptomatic pulmonary embolism developed in three patients, one with a hip replacement and two with a knee replacement; all had received the placebo. There was no significant difference in the prevalence of hemorrhagic episodes or other types of toxicity between the enoxaparin and placebo-treated groups.

Conclusions: Prolonging enoxaparin thromboprophylaxis following hip replacement for a total of four weeks provided therapeutic benefit, by reducing the prevalence of venous thromboembolism, without compromising safety. A similar benefit was not observed in patients treated with knee replacement.

Figures in this Article
    Sign In to Your Personal ProfileSign In To Access Full Content
    Not a Subscriber?
    Get online access for 30 days for $35
    New to JBJS?
    Sign up for a full subscription to both the print and online editions
    Register for a FREE limited account to get full access to all CME activities, to comment on public articles, or to sign up for alerts.
    Register for a FREE limited account to get full access to all CME activities
    Have a subscription to the print edition?
    Current subscribers to The Journal of Bone & Joint Surgery in either the print or quarterly DVD formats receive free online access to JBJS.org.
    Forgot your password?
    Enter your username and email address. We'll send you a reminder to the email address on record.

    Forgot your username or need assistance? Please contact customer service at subs@jbjs.org. If your access is provided
    by your institution, please contact you librarian or administrator for username and password information. Institutional
    administrators, to reset your institution's master username or password, please contact subs@jbjs.org


    Accreditation Statement
    These activities have been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American Academy of Orthopaedic Surgeons and The Journal of Bone and Joint Surgery, Inc. The American Academy of Orthopaedic Surgeons is accredited by the ACCME to provide continuing medical education for physicians.
    CME Activities Associated with This Article
    Submit a Comment
    Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
    Comments are moderated and will appear on the site at the discretion of JBJS editorial staff.

    * = Required Field
    (if multiple authors, separate names by comma)
    Example: John Doe

    Related Content
    The Journal of Bone & Joint Surgery
    JBJS Case Connector
    Topic Collections
    Related Audio and Videos
    PubMed Articles
    Results provided by:
    Clinical Trials
    Readers of This Also Read...
    JBJS Jobs
    Ohio - OhioHealth Research and Innovation Institute (OHRI)
    Oregon - The Center - Orthopedic and Neurosurgical Care and Research
    Georgia - Choice Care Occupational Medicine & Orthopaedics